BioCentury | Aug 28, 2020
Product Development

Aug. 27 Quick Takes: Priority Review for casimersen in DMD, tepotinib in NSCLC; plus asciminib meets in CML and a farewell to digital pioneer Proteus

...date for the once-daily oral c-MET inhibitor, which is approved in Japan as Tepmetko.Novartis says asciminib tops Bosulif...
...the primary endpoint of superiority in major molecular response rate at 24 weeks vs. Bosulif bosutinib...
BioCentury | Oct 12, 2018
Tools & Techniques

iPS cell-derived models offer new opportunities for drug screening

...previously shown to reduce ALS symptoms in mouse models of the disease: leukemia drug Bosulif bosutinib...
...Pfizer Inc. (NYSE:PFE) and rapamycin. In the organ-on-a-chip platform, rapamycin alone or in combination with Bosulif...
...mechanisms driving the synaptic stability phenotype in the Down syndrome model. Allison Johnson Bosulif, bosutinib (PF-05208763, PF-5208763, SKI-606) Harvard Imperial...
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

...approved. Successful co-development deals have led to Avillion’s approval of chronic myelogenous leukemia drug Bosulif bosutinib...
BioCentury | May 26, 2017
Clinical News

Team identifies potential target pathway for ALS

...degeneration in vitro . In a mouse model of the disease, the team said Bosulif bosutinib...
...bosutinib delayed disease onset and increased survival compared with untreated controls. Pfizer Inc. (NYSE:PFE) markets Bosulif...
...inhibitor of BCR-ABL tyrosine kinase (BCR-ABL) and Src kinase, to treat chronic myelogenous leukemia (CML). Alicia Parker bosutinib ABL...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...targeting FK506 binding protein 1A 12kDa (FKBP1A; FKBP12) PKD Phase III Pfizer Inc. (NYSE:PFE) Bosulif bosutinib...
BioCentury | Dec 21, 2016
Clinical News

Bosulif: Ph III BFORE data

...patients with chronic phase Ph+ CML showed that first-line treatment with once-daily 400 mg oral Bosulif...
...with Pfizer to conduct the trial, which Avillion funded (see BioCentury, Jan. 13, 2014 ). Bosulif...
...York, N.Y. Avillion LLP , London, U.K. Product: Bosulif bosutinib ( SKI-606 , PF-5208763 , PF-05208763...
BioCentury | Sep 5, 2016
Company News

Pfizer sales and marketing update

...The U.K.’s NICE issued final guidance recommending the use of Bosulif bosutinib from Pfizer to treat...
...determination. Bosulif is a dual inhibitor of BCR-ABL and Src kinase. NICE had recommended against Bosulif’s...
BioCentury | Aug 2, 2016
Politics & Policy

CVS reveals changes to 2017 formulary

...from Johnson & Johnson (NYSE:JNJ) as a preferred alternative to Xtandi, and will offer Bosulif bosutinib...
...and Sprycel dasatinib as preferred alternatives to the Novartis CML drugs. Pfizer Inc. (NYSE:PFE) markets Bosulif...
BioCentury | Jul 29, 2016
Politics & Policy

Cancer Drugs Fund relaunched

...draft guidance upon reappraisal. The old CDF had covered both. They are leukemia drug Bosulif bosutinib...
BioCentury | Jul 11, 2016
Company News

Pfizer sales and marketing update

...The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Bosulif bosutinib from...
...TKI) and for whom Gleevec imatinib, Tasigna nilotinib and Sprycel dasatinib are not appropriate -- Bosulif’s...
...NICE “on balance” found Bosulif a cost-effective use of NHS resources. The recommended dose for Bosulif...
Items per page:
1 - 10 of 75